Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be$305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of$200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopha ...